摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

甜蜜素 | 139-05-9

中文名称
甜蜜素
中文别名
甜味素;环拉酸钠;环己基氨基磺酸钠;环己胺磺钠;环己;环氨酸钠;环已基氨基磺酸钠;环己基氨基-磺酸钠;甜蜜素(甜味剂)
英文名称
Sodium Cyclamate, analytical standard
英文别名
——
甜蜜素化学式
CAS
139-05-9
化学式
C6H13NNaO3S
mdl
——
分子量
202.23
InChiKey
HBYFMXJSJSZZBM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    >300 °C (lit.)
  • 密度:
    1.58[at 20℃]
  • 溶解度:
    200g/l
  • LogP:
    -2.63 at 20℃

计算性质

  • 辛醇/水分配系数(LogP):
    0.33
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    74.8
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • TSCA:
    Yes
  • 危险品标志:
    Xn
  • 安全说明:
    S36/37
  • 危险类别码:
    R22
  • WGK Germany:
    3
  • 海关编码:
    2929901000
  • RTECS号:
    GV7350000
  • 危险性防范说明:
    P301+P312+P330
  • 危险性描述:
    H302

SDS

SDS:94edb811e30df30cfabff7f4e124c88c
查看

制备方法与用途

化学性质

白色结晶性粉末,无臭,甜度约为蔗糖的40~50倍。溶于水(1g/5mL),微溶于丙二醇(1g/25mL),不溶于乙醇、氯仿、苯和乙醚。其10%水溶液pH值为6.5,不吸湿,不易分解,在酸碱性条件下较为稳定。

生产方法 1. 环己胺和三氧化硫合成法

这是美国Baldwin-Montrose化学公司的生产方法:

  • 将三甲胺与三氧化硫分别溶解于四氯乙烯溶剂中,生成三甲胺-三氧化硫络合物的悬浮液。
  • 再将此悬浮液加入环己胺与氢氧化钠的水溶液,在60~70℃下反应生成环己氨基磺酸钠。收率约95%。
2. 环己胺和氨基磺酸(或盐)合成法

日本吉富制药株式会社采用此方法:

  • 将25g环己胺滴加到10g氨基磺酸和35g轻油的混合物,在165℃下反应3h。
  • 降温至130℃以下,加入41g10%的碳酸氢钠溶液使产物溶解,再蒸馏回收轻油和环己胺,最后粗品重结晶。产率97.5%。
3. 环己胺与氯磺酸合成法

日本某公司采用此方法:

  • 反应方程式:2C6H11NH2 + ClSO3H[<5℃] → C6H11NHSO3NH3C6H11[NaOH] → C6H11NHSO3Na。
  • 该法原料便宜,反应快,但副反应较多,设备腐蚀严重。
其他生产方法 环己胺和三氧化硫合成法

这是一种美国Baldwin-Montrose化学公司的具体实施步骤:

  • 将40g液态SO3溶解于200mLCH2C12中。
  • 在-I0℃下滴加到含56g三乙胺的溶液中,生成三乙胺三氧化硫络合物。再将此悬浮液加入环己胺与氢氧化钠的水溶液,在60~70℃反应生成环己氨基磺酸钠。收率约95%。
日本东洋化学药品株式会社方法
  • 反应温度在160~179℃之间,溶剂为邻二氯苯。
  • 未反应的环己胺和邻二氯苯用水蒸气蒸出后重新使用。收率高且原料成本低。
性能与用途

无营养甜味剂,适用于糖尿病患者等需要控制糖分摄入的人群,可广泛用于食品、饮料等行业。其生产方法多样,可根据实际情况选择合适的工艺流程来降低成本并提高产品质量。

文献信息

  • Pharmaceutical preparation comprising an active dispersed on a matrix
    申请人:——
    公开号:US20040058896A1
    公开(公告)日:2004-03-25
    The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.
    本发明涉及制药技术领域,描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中,活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
  • Dosage form containing (s)-pantoprazole as active ingredient
    申请人:Dietrich Rango
    公开号:US20060216346A1
    公开(公告)日:2006-09-28
    Dosage forms for the oral administration of the magnesium salt of (S)-pantoprazole are described.
    描述了口服镁盐(S)-泮托拉唑的剂型。
  • Immunostimulating 7-deaza-7-oxa-and 7-deaza-7-thia-analogs of 8-substituted-guanine-9-(1'-beta-d-aldoglycosidyl) derivatives, compositions and methods
    申请人:SCRIPPS CLINIC AND RESEARCH FOUNDATION
    公开号:EP0343945A2
    公开(公告)日:1989-11-29
    An immune response-enhancing guanosine analog derivative having a structure that conforms to the formula wherein Z is oxygen (O) or sulfur (S); X is oxygen (O), sulfur (S) selenium (Se) or cyanimino 9NCN); and R₁ is an aldoglycoside is disclosed. Also disclosed are a composition containing the guanosine analog derivative as active ingredient and a method of using the composition for immunostimulation.
    一种免疫应答增强鸟苷类似物衍生物,其结构符合式 其中 Z 是氧(O)或硫(S);X 是氧(O)、硫(S)、硒(Se)或氰基氨基 9NCN;R₁ 是醛糖苷。还公开了一种含有鸟苷类似衍生物作为活性成分的组合物,以及使用该组合物进行免疫刺激的方法。
  • Immunostimulating guanine derivatives, compositions and methods
    申请人:SCRIPPS CLINIC AND RESEARCH FOUNDATION
    公开号:EP0341066A2
    公开(公告)日:1989-11-08
    7,8-Disubstituted guanosine nucleoside derivatives are found to be potent immune response enhancing agents in human and animal cells. 7-Substituents are heteroatom-substituted-hydrocarbyl radicals having a length greater than ethyl and less than about decyl. 8-Substituents are =O, =S, =Se and =NCN. Compositions and methods of use are also disclosed.
    研究发现,7,8-二取代鸟苷核苷衍生物可有效增强人类和动物细胞的免疫反应。7-取代基是杂原子取代的烃基,其长度大于乙基,小于癸基。8-取代基是=O、=S、=Se 和=NCN。还公开了组合物和使用方法。
  • CARBONATED DRINKS
    申请人:San-Ei Gen F.F.I., Inc.
    公开号:EP1364587A1
    公开(公告)日:2003-11-26
    A carbonated drink having both the rich taste of a plant-derived component(s) such as fruit juice(s) and the stimulating and refreshing feel of carbonic acids is provided. The carbonated drink contains 10 to 80% by weight of the plant-derived component(s) and 2% by volume or ,more of carbon dioxide, has a soluble solids content of not more than 8 degree as indicated by a refractive saccharometer, contains high intensity sweetener(s), the sweetness due to which is not less than 25% by weight( on the sucrose equivalent basis), and has an entire sweetness equivalent to the sweetness of a sucrose content of 8 to 14% by weight. Furthermore, it contains sucralose as at least one high intensity sweetener, with the sweetness due to sucralose accounting for not less than 50 % of the sweetness due to all high intensity sweetener (s) on the sucrose equivalent basis.
    本发明提供了一种碳酸饮料,既有果汁等植物提取成分的浓郁口感,又有碳酸的刺激和清爽感。这种碳酸饮料含有 10%至 80%(按重量计)的植物提取成分和 2%(按体积计)或更多的二氧化碳,用折光糖度计显示可溶性固体含量不超过 8 度,含有高浓度甜味剂,其甜度不低于 25%(按重量计)(以蔗糖当量为基础),且整个甜度相当于蔗糖含量为 8%至 14%(按重量计)的甜度。此外,它还含有蔗糖素(三氯蔗糖)作为至少一种高甜度甜味剂,按蔗糖当量计算,蔗糖素(三氯蔗糖)的甜度不低于所有高甜度甜味剂甜度的 50%。
查看更多

同类化合物

甜蜜素 环拉酸 异米尼尔环璜酸盐 二环己基氨基磺酸 4-[(2S)-2-氨基-4-(甲基硫烷基)丁酰]-L-α-谷氨酰-3-(4H-咪唑-4-基)-L-丙氨酰-L-苯丙氨酸 4-(二甲基氨基)-2-异丙基-2-苯基戊腈环璜酸盐 5-methyl-2-(1-methylethyl)cyclohexyl (3aR,7aS)-rel-hexahydro-1,2,3-benzothiazole-3(3aH)-carboxylate 2,2-dioxide 5-methyl-2-(1-methylethyl)cyclohexyl (3aR,7aS)-rel-hexahydro-1,2,3-benzothiazole-3(3aH)-carboxylate 2,2-dioxide [(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl] 2,2-dioxo-3a,4,5,6,7,7a-hexahydrobenzo[d]oxathiazole-3-carboxylate 5,6-dihydro-1'-(2-thienyl-methyl)spiro[imidazo[2,1-b][3]benzazepine-11-[11H],4'-piperidine] cyclohexylsulfamate (1:1) 2,2,2-trichloroethyl cyclohexylsulfamate [Bi(CycH)3] (-)-3,18-(2,2-dioxido-1,2,3-oxathiazinan-3-yl)-13-methyl-17-norkauran-16-one ethylmethyl-5-(tetrahydro-2-furanyl)pentylsulfonium cyclohexylsulfamate Phenylephrine cyclohexylsulfamate Magnesium cyclamate Silver cyclamate Sulfamic acid, (3-methylcyclohexyl)- 2-(p-Methoxy-alpha-(1-piperidyl)benzyl)cyclohexanol cyclohexanesulfamate Barium cyclohexanesulfamate Butyranilide, 2'-ethyl-3-(2-methoxyethyl)amino-3-methyl-, cyclohexane sulfamate 1-(4-Cyclopropyl-phenyl)-2-methylamino-ethanol; compound with cyclohexyl-sulfamic acid Cyclohexylsulfamic acid--3-(1-butylpyrrolidin-2-yl)-1H-indole (1/1) Cyclohexylsulfamic acid--1-benzyl-3-(1-methylpyrrolidin-2-yl)-1H-indole (1/1) (+)-Furfurylmethyl(alpha-methylphenethyl)ammonium cyclohexylsulphamate Cyclamate magnesium dihydrate potassium cyclohexylsulfamate Cyclohexylsulfamic acid--1-(4-chlorophenyl)-N-[(furan-2-yl)methyl]-N-methylpropan-2-amine (1/1) Cyclohexylsulfamic acid--N-[(furan-2-yl)methyl]-N-methyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine (1/1) Calcium cyclamate N-Nitrosocyclohexylsulfamic acid 3,4,5,6-tetrahydro-6-methyl-3-benzylspiro[1,2,3-oxathiazine-2,2-dioxide-4-cyclohexane] (R)-1,1,1-Trichloro-4-(hex-5-yn-1-ylamino)-4-oxobutan-2-yl (5R,8R)-8-methyl-4-methylene-7-oxo-2-azabicyclo[3.3.1]nonane-2-sulfonate ethanol-cyclam (2S,3R)-2,3-dihydroxy-3-phenyl-1-[(1S,2R,6S,7R)-7,10,10-trimethyl-4,4-dioxo-3-oxa-4lambda6-thia-5-azatricyclo[5.2.1.02,6]decan-5-yl]propan-1-one (2S)-2,3-dihydroxy-1-[(1S,2R,6S,7R)-7,10,10-trimethyl-4,4-dioxo-3-oxa-4lambda6-thia-5-azatricyclo[5.2.1.02,6]decan-5-yl]propan-1-one 2,2,2-Trichloroethyl 2,2-dioxo-3-oxa-2lambda6-thia-1,4-diazaspiro[5.5]undecane-4-carboxylate (2S,3R)-3-cyclohexyl-2,3-dihydroxy-1-[(1S,2R,6S,7R)-7,10,10-trimethyl-4,4-dioxo-3-oxa-4lambda6-thia-5-azatricyclo[5.2.1.02,6]decan-5-yl]propan-1-one Sodium dicyclohexylsulfamate Sodium N-ethylcyclohexylsulfamate Barium(2+);cyclohexylsulfamic acid 2,2,2-Trichloroethyl 7-azabicyclo[4.1.0]heptane-7-sulfonate (2-oxo-cyclohexyl)sulfamic acid 2,2,2-trichloroethyl ester [(1S,2R,5S,7S,10S,11S,13R,17S,20R)-10,20-dimethyl-15,15-dioxo-16-oxa-15lambda6-thia-14-azapentacyclo[11.6.1.02,11.05,10.017,20]icosan-7-yl]oxy-tri(propan-2-yl)silane methyl 1-benzyl-3-pyrrolidineacetate cyclohexylsulfamate 2,2,2-Trichloroethyl 3-azatricyclo[3.2.1.02,4]octane-3-sulfonate [(2R)-3-carboxy-2-hydroxypropyl]-trimethylazanium;N-cyclohexylsulfamate azane;cyclohexylsulfamic acid (1,2,3-Trimethylcyclohexyl)sulfamic acid Beta-diethylaminoethyl-p-aminobenzoate cyclohexylsulfamate